Literature DB >> 29490428

DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions.

Ayodele Gomih1, Jennifer S Smith1,2, Kari E North1, Michael G Hudgens3, Wendy R Brewster2,4, Zhiqing Huang5, David Skaar6, Fidel Valea7, Rex C Bentley8, Adriana C Vidal9, Rachel L Maguire6, Randy L Jirtle6,10, Susan K Murphy5, Cathrine Hoyo6.   

Abstract

The role of host epigenetic mechanisms in the natural history of low-grade cervical intraepithelial neoplasia (CIN1) is not well characterized. We explored differential methylation of imprinted gene regulatory regions as predictors of the risk of CIN1 regression. A total of 164 patients with CIN1 were recruited from 10 Duke University clinics for the CIN Cohort Study. Participants had colposcopies at enrollment and up to five follow-up visits over 3 years. DNA was extracted from exfoliated cervical cells for methylation quantitation at CpG (cytosine-phosphate-guanine) sites and human papillomavirus (HPV) genotyping. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox regression to quantify the effect of methylation on CIN1 regression over two consecutive visits, compared to non-regression (persistent CIN1; progression to CIN2+; or CIN1 regression at a single time-point), adjusting for age, race, high-risk HPV (hrHPV), parity, oral contraceptive and smoking status. Median participant age was 26.6 years (range: 21.0-64.4 years), 39% were African-American, and 11% were current smokers. Most participants were hrHPV-positive at enrollment (80.5%). Over one-third of cases regressed (n = 53, 35.1%). Median time-to-regression was 12.6 months (range: 4.5-24.0 months). Probability of CIN1 regression was negatively correlated with methylation at IGF2AS CpG 5 (HR = 0.41; 95% CI = 0.23-0.77) and PEG10 DMR (HR = 0.80; 95% CI = 0.65-0.98). Altered methylation of imprinted IGF2AS and PEG10 DMRs may play a role in the natural history of CIN1. If confirmed in larger studies, further research on imprinted gene DMR methylation is warranted to determine its efficacy as a biomarker for cervical cancer screening.
© 2018 UICC.

Entities:  

Keywords:  HPV; cervical cancer; epigenetics; imprinted genes; methylation; neoplasia

Mesh:

Year:  2018        PMID: 29490428      PMCID: PMC6019167          DOI: 10.1002/ijc.31350

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  38 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 2.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5.

Authors:  Minjie Du; Linda G Beatty; Wenjing Zhou; Jocelyne Lew; Christopher Schoenherr; Rosanna Weksberg; Paul D Sadowski
Journal:  Hum Mol Genet       Date:  2003-08-01       Impact factor: 6.150

4.  Expression profile of LIT1/KCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers.

Authors:  Seiji Nakano; Kazuhiro Murakami; Makiko Meguro; Hidenobu Soejima; Ken Higashimoto; Takeshi Urano; Hiroyuki Kugoh; Tsunehiro Mukai; Masahide Ikeguchi; Mitsuo Oshimura
Journal:  Cancer Sci       Date:  2006-09-05       Impact factor: 6.716

5.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 6.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

7.  Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer.

Authors:  Jun Zhang; Tingting Yao; Zhongqiu Lin; Yali Gao
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

8.  Tobacco smoking leads to extensive genome-wide changes in DNA methylation.

Authors:  Sonja Zeilinger; Brigitte Kühnel; Norman Klopp; Hansjörg Baurecht; Anja Kleinschmidt; Christian Gieger; Stephan Weidinger; Eva Lattka; Jerzy Adamski; Annette Peters; Konstantin Strauch; Melanie Waldenberger; Thomas Illig
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.

Authors:  Yoko Ito; Thibaud Koessler; Ashraf E K Ibrahim; Sushma Rai; Sarah L Vowler; Sayeda Abu-Amero; Ana-Luisa Silva; Ana-Teresa Maia; Joanna E Huddleston; Santiago Uribe-Lewis; Kathryn Woodfine; Maja Jagodic; Raffaella Nativio; Alison Dunning; Gudrun Moore; Elena Klenova; Sheila Bingham; Paul D P Pharoah; James D Brenton; Stephan Beck; Manjinder S Sandhu; Adele Murrell
Journal:  Hum Mol Genet       Date:  2008-06-09       Impact factor: 6.150

10.  PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer.

Authors:  A C Vidal; N M Henry; S K Murphy; O Oneko; M Nye; J A Bartlett; F Overcash; Z Huang; F Wang; P Mlay; J Obure; J Smith; B Vasquez; B Swai; B Hernandez; C Hoyo
Journal:  Clin Transl Oncol       Date:  2013-06-18       Impact factor: 3.405

View more
  3 in total

1.  IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression.

Authors:  Lin Zhang; Yicong Wan; Zihan Zhang; Yi Jiang; Zhiyue Gu; Xiaoling Ma; Sipei Nie; Jing Yang; Jinghe Lang; Wenjun Cheng; Lan Zhu
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

2.  Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia.

Authors:  Claire Bosire; Adriana C Vidal; Jennifer S Smith; Dereje Jima; Zhiqing Huang; David Skaar; Fidel Valea; Rex Bentley; Margaret Gradison; Kimberly S H Yarnall; Anne Ford; Francine Overcash; Susan K Murphy; Cathrine Hoyo
Journal:  Infect Agent Cancer       Date:  2021-06-13       Impact factor: 2.965

3.  ZNF471 modulates EMT and functions as methylation regulated tumor suppressor with diagnostic and prognostic significance in cervical cancer.

Authors:  Samatha Bhat; Shama Prasada Kabekkodu; Divya Adiga; Rayzel Fernandes; Vaibhav Shukla; Poonam Bhandari; Deeksha Pandey; Krishna Sharan; Kapaettu Satyamoorthy
Journal:  Cell Biol Toxicol       Date:  2021-02-10       Impact factor: 6.691

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.